These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1450043)

  • 21. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients.
    Ralston SH; Gallacher SJ; Patel U; Campbell J; Boyle IT
    Ann Intern Med; 1990 Apr; 112(7):499-504. PubMed ID: 2138442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
    Major P
    Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of available medical therapy for hypercalcemia of malignancy.
    Mundy GR; Wilkinson R; Heath DA
    Am J Med; 1983 Mar; 74(3):421-32. PubMed ID: 6219578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
    Young G; Shende A
    Med Pediatr Oncol; 1998 Feb; 30(2):117-21. PubMed ID: 9403021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the medical treatment of hypercalcemia of malignancy.
    Hall TG; Schaiff RA
    Clin Pharm; 1993 Feb; 12(2):117-25. PubMed ID: 8453860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypercalcemia and childhood cancer: a 7-year experience.
    Kerdudo C; Aerts I; Fattet S; Chevret L; Pacquement H; Doz F; Michon J; Garabedian M; Orbach D
    J Pediatr Hematol Oncol; 2005 Jan; 27(1):23-7. PubMed ID: 15654274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
    Major PP; Coleman RE
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    Thiébaud D; Jacquet AF; Burckhardt P
    Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
    Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B
    Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An audit of the management of malignant hypercalcaemia.
    Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
    Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salmon calcitonin in the acute management of hypercalcemia.
    Wisneski LA
    Calcif Tissue Int; 1990; 46 Suppl():S26-30. PubMed ID: 2137363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
    Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
    Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symptomatic hypocalcemia following combined calcitonin and mithramycin therapy for hypercalcemia due to malignancy.
    Caro JF; Besarab A; Glennon JA
    Cancer Treat Rep; 1978 Oct; 62(10):1561-3. PubMed ID: 152145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptomatic hypercalcaemia in lung cancer.
    Campbell JH; Ralston S; Boyle IT; Banham SW
    Respir Med; 1991 May; 85(3):223-7. PubMed ID: 1831917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
    Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
    J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
    Sawyer N; Newstead C; Drummond A; Cunningham J
    Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
    Davis JR; Heath DA
    Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.